NASDAQ:SMMT Summit Therapeutics Q2 2025 Earnings Results & Report $15.13 -0.39 (-2.51%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$15.11 -0.02 (-0.11%) As of 10/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Summit Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 11, 2025. The company reported EPS of -$0.76 versus the -$0.10 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 11, 2025TimeBefore Market OpensConference Call7:00 AM ET Summit Therapeutics EPS ResultsActual EPS-$0.76Consensus EPS -$0.10Beat/MissMissed by -$0.66One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersSummit Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSummit Therapeutics' Q3 2026 earnings is estimated for Monday, October 19, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Summit Therapeutics Q2 2025 Earnings FAQ Did Summit Therapeutics beat earnings estimates for Q2 2025? Summit Therapeutics (NASDAQ:SMMT) reported earnings of -$0.76 per share for Q2 2025, missing the consensus estimate of -$0.10. The report was announced on Monday, August 11, 2025. When is Summit Therapeutics' next earnings date? Summit Therapeutics' next earnings date is estimated for Monday, October 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Summit Therapeutics on the company's earnings history page. Summit Therapeutics Earnings HeadlinesSummit Therapeutics (SMMT) Projected to Release Earnings on MondayOctober 12 at 1:26 AM | americanbankingnews.comSummit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial CollaborationOctober 2, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus IvonescimabOctober 2, 2026 | rttnews.comSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayOctober 2, 2026 | businesswire.comDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesOctober 2, 2026 | businesswire.comSee More Summit Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email. Email Address About Summit TherapeuticsSummit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer. Summit obtained exclusive rights from Akeso, Inc. to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories. Akeso retains rights in China and certain related markets. The program is being advanced through clinical development and regulatory activities intended to assess its safety and effectiveness as a potential treatment for patients with cancer. Founded in the United Kingdom, Summit historically worked on therapies for infectious diseases, including the investigational antibiotic ridinilazole for Clostridioides difficile infection, before shifting its strategic focus to oncology. The company is led by Robert W. Duggan, who serves as chairman and chief executive officer. Summit Therapeutics is headquartered in Miami, Florida, and its ordinary shares trade on the Nasdaq under the symbol SMMT.View Summit Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
